Forte Biosciences, Inc. (FBRX): Nasdaq/NYSE listing notice — Forte Biosciences receives Nasdaq bid price deficiency notice; 180 days to comply

Forte Biosciences, Inc.

Received Nasdaq notice on Sept 14, 2023 for bid price below $1.00 for 30 consecutive business days.
Has 180 calendar days, until March 12, 2024, to regain compliance by closing bid price >= $1.00 for 10 consecutive business days.
No immediate impact on listing or trading; may be eligible for additional 180-day compliance period if needed.
Intends to monitor bid price and consider options, including potential reverse stock split to cure deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Forte Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

September 14, 2023, Forte Biosciences, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar

View on SEC.gov

Browse all listing & compliance notices →

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-238557

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.